More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
Hospitals and health systems may apply through Feb. 19 for the 2019 AHA Equity of Care Award, which recognizes organizations participating in the AHA's #…
Headline
The American Board of Medical Specialties has released an updated guide to the specialty and subspecialty certifications offered by its 24 member boards.
Headline
The AHA and the Federation of American Hospitals today urged Congress to oppose any legislation that would repeal current law limiting self-referral to…
Headline
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
Headline
Joseph Miller, vice president of behavioral health care transformation services at Hackensack (N.J.) Meridian Health, will serve as 2019 chair of the AHA's…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.